Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Experimental drug treatment tofersen may be useful for treating inherited form of ALS

Staff Writer
Staff Writer 2 years ago
Updated 2021/10/23 at 2:32 PM
Share
SHARE

A study in the New England Journal of Medicine highlights the results of phase 1/2 clinical trial involving the experimental drug treatment tofersen, also known as BIIB067.

According to researchers at the Washington University School of Medicine, tofersen may be effective at reducing the severity of the inherited form of amyotrophic lateral sclerosis (ALS). The progressive neurodegenerative disease is caused by a mutation in the gene SOD1.

“Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations,” the findings read.

In the study, 50 participants received doses of either tofersen or placebo, administered for 12 weeks.

“A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture–related adverse events were observed in most participants,” the co-authors stated in the findings.

“In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture–related adverse events were observed in most participants.”

The findings provide a glimpse of what is a potential drug treatment efficient at combating the effects of ALS, however, more research is needed.

Photo: kirstypargeter

You Might Also Like

Hallucinogen use in America has increased since 2015 for adults

Pregnant women with epilepsy may be at more risk of depression and anxiety symptoms

Researchers find high cholesterol may not raise the risk of dementia

Study unveils the leisure activities that may lower the risk of dementia

MIT study shows how microglia can contribute to Alzheimer’s disease

TAGGED: tofersen, ALS, amyotrophic lateral sclerosis
Staff Writer July 8, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article A US-based study shows the state of gender bias and equal rights
Next Article Older adults with dual sensory impairment at a higher risk of dementia

Recommended

Clinical

Hallucinogen use in America has increased since 2015 for adults

1 Min Read
Clinical

Pregnant women with epilepsy may be at more risk of depression and anxiety symptoms

1 Min Read
Clinical

Researchers find high cholesterol may not raise the risk of dementia

1 Min Read
Clinical

Study unveils the leisure activities that may lower the risk of dementia

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?